Software company Induction Healthcare Group PLC (AIM: INHC) announced on Monday that it has been selected by the Health Service Executive (HSE) of the Republic of Ireland to provide its Attend Anywhere video platform as the national clinical video solution.
Starting 1 January 2025, the platform will be rolled out across Ireland's healthcare system, initially focusing on the acute sector.
The two-year contract, with the option for a third year, will provide a minimum of 1,500 licences, generating at least GBP0.3m in annual recurring revenue (ARR). HSE plans to scale usage to over 3,000 clinical users in the near term.
Attend Anywhere was chosen over generic solutions like Teams and Zoom due to its advanced waiting room functionality, enhanced security features and user-friendly interface for administrators.
Induction's software solutions, including Attend Anywhere, help healthcare providers deliver care both remotely and face-to-face, integrated with leading Electronic Medical Record platforms. The company's applications are trusted by national and regional healthcare systems across the UK and Ireland, serving hundreds of thousands of clinicians and millions of patients.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules